Unknown

Dataset Information

0

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.


ABSTRACT: Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. However, the precise mechanisms underlying the antagonistic effects remain unclear. In the present study, we investigated the role of exosomes in the antagonistic effects of concurrent administration of chemotherapy and TKIs. Exosomes derived from gefitinib-treated PC9 cells (Exo-GF) decreased the antitumor effects of cisplatin, while exosomes derived from cisplatin-treated PC9 cells (Exo-DDP) did not significantly affect the antitumor effects of gefitinib. Additionally, inhibition of exosome secretion by GW4869 resulted in a modest synergistic effect when cisplatin and gefitinib were co-administered. Furthermore, Exo-GF co-incubation with cisplatin increased autophagic activity and reduced apoptosis, as demonstrated by an upregulation of LC3-II and Bcl-2 protein levels and downregulation of p62 and Bax protein levels. Thus, the antagonistic effects of gefitinib and cisplatin were mainly attributed to Exo-GF, which resulted in upregulated autophagy and increased cisplatin resistance. These results suggest that inhibition of exosome secretion may be a helpful strategy to overcome the antagonistic effects when TKIs and chemotherapeutic agents are co-administered. Before administering chemotherapy, introducing a washout period to completely eliminate TKI-related exosomes, may be a better procedure for administering chemotherapy and TKIs.

SUBMITTER: Li XQ 

PROVIDER: S-EPMC5029725 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.

Li Xiao-Qiu XQ   Liu Jia-Tao JT   Fan Lu-Lu LL   Liu Yu Y   Cheng Liang L   Wang Fang F   Yu Han-Qing HQ   Gao Jian J   Wei Wei W   Wang Hua H   Sun Guo-Ping GP  

Oncotarget 20160401 17


Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. However, the precise mechanisms underlying the antagonistic effects remain unclear. In the present study, we investigated the role of exosomes in the antagonistic effects of concurrent administration of chemotherapy and TKIs. Exosomes derived from gef  ...[more]

Similar Datasets

| S-EPMC7515841 | biostudies-literature
| S-EPMC7997352 | biostudies-literature
| S-EPMC3186869 | biostudies-literature
| S-EPMC7704378 | biostudies-literature
| S-EPMC8474244 | biostudies-literature
| S-EPMC3261336 | biostudies-literature
2019-12-31 | GSE123066 | GEO
| S-EPMC5558834 | biostudies-literature
| S-EPMC5228548 | biostudies-literature
| S-EPMC5385032 | biostudies-literature